RARG and cancer: Pharmacologic activation of RARα, or inhibition of RARγ activity, reduces cancer cell growth in vitro, thereby suggesting that a specific RARα agonist would be a more effective method of cancer treatment than an RAR pan-agonist such us ATRA.